Dentsu Announces Its Corporate Venture Capital Fund

TOKYO

Dentsu Inc. (TOKYO: 4324; ISIN: JP3551520004; President & CEO: Tadashi Ishii; Head Office: Tokyo; Capital: 74,609.81 million yen) announced today that Dentsu Ventures Global Fund I (hereinafter “Dentsu Ventures”), the Company’s corporate venture capital fund, has made an investment in Cue Inc. (CEO: Ayub Khattak; Head Office: San Diego), a U.S. technology company that created Cue, an at-home device for tracking health information at the molecular level.

Dentsu Ventures was established in April of this year with the objectives of investing in ambitious start-up companies that will create an as yet unseen future and furthering open innovation across the Dentsu Group through collaboration with investees. In addition to funding, Dentsu Ventures will support businesses and entrepreneurs by providing problem-solving solutions and resources that are unique to the Group. Cue Inc. is the fifth company in which Dentsu Ventures has invested.

Cue Inc. has developed a cube-shaped hardware device into which diagnostic cartridges are inserted to provide easy at-home analysis of healthcare data at the molecular level, together with a smartphone application that can manage the results of the analysis. Through a small sample of blood, saliva or mucus that has been collected and added to a color-coded cartridge which is then inserted into the Cue hardware device, a user can easily track health indicators such as vitamin D, testosterone, inflammation, influenza and fertility. After approval from the relevant authorities has been obtained, the company aims to launch the product in the EU and Hong Kong in the second quarter of 2016. It should be available in the U.S. sometime during 2016 and in Japan in 2017. In the future, it is expected that Cue will be able to handle twenty health indicators.

Amid a growing consumer interest in health, Dentsu Ventures believes that the importance of Cue Inc.’s technology, which enables users to easily analyze biological information at the molecular level and can be used to promote health and wellbeing, will grow in the future. Looking ahead, the Dentsu Group will provide support for the dissemination of the Cue healthcare device worldwide and the other new businesses that the company will develop in the future.

[About the Dentsu Group]

Dentsu is the world’s largest advertising agency brand. Led by Dentsu Inc. (Tokyo: 4324; ISIN: JP3551520004), a company with a history of 114 years of innovation, the Dentsu Group provides a comprehensive range of client-centric brand, integrated communications, media and digital services through its nine global network brands—Carat, Dentsu, Dentsu media, iProspect, Isobar, mcgarrybowen, MKTG, Posterscope and Vizeum—as well as through its specialist/multi-market brands including Amnet, Amplifi, Data2Decisions, Mitchell Communications (PR) and 360i.

The Dentsu Group has a strong presence in 124 countries across five continents, and employs more than 43,000 dedicated professionals. Dentsu Aegis Network Ltd., its global business headquarters in London, oversees Dentsu’s agency operations outside of Japan. The Group is also active in the production and marketing of sports and entertainment content on a global scale.

www.dentsu.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151224005037/en/